Vaxil BioTherapeutics
Developing Cancer and Tuberculosis Vaccines
Company Overview
Snapshot
Founded in February 2007 by Lior Carmon, Vaxil BioTherapeutics operates with 1–10 employees. The company has raised $6.35M across 4 funding rounds from 2 investors. A significant milestone for the company was its public listing on TASE in March 2016.
Business overview
Vaxil BioTherapeutics is a clinical-stage company focused on developing immunotherapeutic products, including long peptide vaccines and antibodies, to treat cancer and infectious diseases. The company's core technology, VaxHit, utilizes signal peptide domains in selected targets as core antigens. Vaxil's lead product, ImMucin, has received orphan drug designation for multiple myeloma and has completed a phase 1/2 clinical trial. The company also develops anti-MUC1 SP antibodies (SPmAb-2.1 and SPmAb-6) and a vaccine against mycobacterium tuberculosis, MTBuVax, which is in preclinical studies. Vaxil operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, serving markets in Israel, Canada, and the United States.
Strategic signal
In May 2024, Vaxil Bio entered into a Letter of Intent with Green Data regarding a proposed reverse takeover. This development signals a potential strategic shift or restructuring for the company, indicating a significant change in its corporate direction or ownership structure that could impact its future operations and market positioning.
Log in to access full profile ›Company Intelligence Q&A
- When did Vaxil BioTherapeutics go public?
- Vaxil BioTherapeutics went public on TASE in March 2016.
- What is the status of Vaxil BioTherapeutics' lead product, ImMucin?
- ImMucin has received EMA and FDA orphan drug designation for multiple myeloma and has successfully completed a phase 1/2 clinical trial. Vaxil is also performing an additional phase 1/2 study with ImMucin in metastatic breast cancer patients.
- What significant corporate event did Vaxil BioTherapeutics announce in May 2024?
- In May 2024, Vaxil Bio entered into a Letter of Intent with Green Data regarding a proposed reverse takeover.
- What is Vaxil BioTherapeutics' total funding?
- Vaxil BioTherapeutics has raised a total of $6.35M across 4 funding rounds.